Cognitive Neurology and Alzheimer's Research Centre, St. Joseph's Hospital
London, Ontario, N6A 3T8, Canada
NCT Number: NCT01002300
Investigations into the components of cognition damaged in frontotemporal dementia (FTD) demonstrate that patients with FTD show deficits in facial and verbal expression recognition, lack insight into what others think or might do (theory of mind skills), and in decision making tasks requiring processing of positive versus negative feedback. These cognitive functions are thought to be critical for appropriate social behavioural regulation (Blair, 2003). Recent studies in animal models and humans suggest that the neuropeptide oxytocin is an important mediator of social behavior and that oxytocin may facilitate emotion recognition, theory of mind processing, and prosocial behaviors (Donaldson and Young, 2008). Together, these findings suggest that upregulation of oxytocin dependent mechanisms of social and emotional cognition may be a valuable treatment approach in patients with FTD. The aim of this study is to determine how administration of intranasal oxytocin to patients with frontotemporal dementia affects behavior and processing of specific types of social and emotional information.The investigators' hypothesis is that oxytocin administration will improve emotional and social cognitive deficits in patients with FTD, resulting in improved decision making and behaviour.
Looking for future studies?
Notify Me30 year–80 year
All sexes
Interventional
Not applicable
London, Ontario, N6A 3T8, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
Other names: Syntocinon
Time frame: Day of treatment
Time frame: One week following treatment
Time frame: 1 week after treatment
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Other
Investigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal Dementia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04060082
Brain Diseases, Central Nervous System Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT04165213
Alzheimer Disease, Arterial Occlusive Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04937452
Aphasia, Aphasia, Primary Progressive
Rome, <None>, Italy
View Trial DetailsNCT01386333
Brain Diseases, Central Nervous System Diseases
London, Ontario, Canada
View Trial Details